Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for...
Saved in:
Main Authors: | Emanuelle B. Gaspar (Author), Carlos Roberto Prudencio (Author), Elizabeth De Gaspari (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring
by: Amanda Izeli Portilho, et al.
Published: (2024) -
Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
by: Khalid Hajissa, et al.
Published: (2021) -
Are the new SARS-CoV-2 variants resistant against the vaccine?
by: Mohnad Abdalla, et al.
Published: (2021) -
Impact of meningococcal group B OMV vaccines, beyond their brief
by: Helen Petousis-Harris
Published: (2018) -
A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
by: Edward J. Quinlan, et al.
Published: (2022)